

Efficacy and safety of risankizumab in moderate-to-severe
ulcerative colitis: a risankizumab-controlled phase 3 trials

Lancet, The

392, 650-661

DOI: [10.1016/s0140-6736\(18\)31713-6](https://doi.org/10.1016/s0140-6736(18)31713-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3879-3883.	2.0	49
2	Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. <i>Psoriasis: Targets and Therapy</i> , 2018, Volume 8, 83-92.	1.2	9
3	Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1489-1497.	0.9	13
4	Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases. <i>Current Allergy and Asthma Reports</i> , 2018, 18, 55.	2.4	9
5	Risankizumab for psoriasis. <i>Lancet</i> , The, 2018, 392, 616-617.	6.3	4
6	Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials. <i>Clinical Pharmacokinetics</i> , 2019, 58, 375-387.	1.6	25
7	Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. <i>Lancet</i> , The, 2019, 394, 831-839.	6.3	250
8	Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. <i>PLoS ONE</i> , 2019, 14, e0220868.	1.1	118
9	Risankizumab in the treatment of psoriasis – literature review. <i>Reumatologia</i> , 2019, 57, 158-162.	0.5	22
10	The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1167-1178.	0.5	152
11	Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the Susta-IMM phase 2/3 trial. <i>Journal of Dermatology</i> , 2019, 46, 686-694.	0.6	70
12	Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies. <i>AAPS Journal</i> , 2019, 21, 82.	2.2	9
13	Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1656-1668.	1.0	24
14	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 394, 576-586.	6.3	198
15	Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America. <i>Advances in Therapy</i> , 2019, 36, 3446-3457.	1.3	1
16	Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children. <i>Children</i> , 2019, 6, 108.	0.6	31
17	Psoriasis: Past, Present, and Future. <i>Journal of Investigative Dermatology</i> , 2019, 139, e133-e142.	0.3	23
18	Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis. <i>Frontiers in Pharmacology</i> , 2019, 10, 872.	1.6	65

#	ARTICLE	IF	CITATIONS
19	Precision medicine in psoriatic arthritis: how should we select targeted therapies?. <i>Lancet Rheumatology, The</i> , 2019, 1, e66-e73.	2.2	4
20	Risankizumab for the treatment of psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 851-857.	1.3	10
21	Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2019, 75, 105841.	1.7	13
22	The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1031-1041.	1.0	12
23	Predicting Clinical Responses to Ustekinumab. <i>JAMA Dermatology</i> , 2019, 155, 1227.	2.0	1
24	Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Journal of Immunology Research</i> , 2019, 2019, 1-25.	0.9	113
25	Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 943-949.	0.6	26
26	Update on Risankizumab for Psoriasis. <i>Current Dermatology Reports</i> , 2019, 8, 1-5.	1.1	0
27	Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature. <i>Current Dermatology Reports</i> , 2019, 8, 6-13.	1.1	0
28	State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. <i>Current Opinion in Pharmacology</i> , 2019, 46, 90-99.	1.7	34
29	Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2019, 21, 35.	2.1	11
30	Personalized medicine—concepts, technologies, and applications in inflammatory skin diseases. <i>Apmis</i> , 2019, 127, 386-424.	0.9	36
31	Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase III Clinical Trials. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1309-1321.	1.6	25
32	A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 102-110.	0.6	52
33	Risankizumab: First Global Approval. <i>Drugs</i> , 2019, 79, 893-900.	4.9	48
34	Antagonizing Retinoic Acid-Related-Orphan Receptor Gamma Activity Blocks the T Helper 17/Interleukin-17 Pathway Leading to Attenuated Pro-inflammatory Human Keratinocyte and Skin Responses. <i>Frontiers in Immunology</i> , 2019, 10, 577.	2.2	26
35	Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1676-1684.	1.3	64
36	The Immunobiology of the Interleukin-12 Family: Room for Discovery. <i>Immunity</i> , 2019, 50, 851-870.	6.6	298

#	ARTICLE	IF	CITATIONS
37	What's New in Psoriasis. <i>Dermatologic Clinics</i> , 2019, 37, 129-136.	1.0	15
38	Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 473-479.	1.9	30
39	IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101604.	1.0	28
40	Risankizumab for the treatment of plaque psoriasis in adults. <i>The Prescriber</i> , 2019, 30, 33-35.	0.1	0
41	Risankizumab in moderate-to-severe plaque psoriasis. <i>Immunotherapy</i> , 2019, 11, 1357-1370.	1.0	5
42	Drug updates and approvals. <i>Nurse Practitioner</i> , 2019, 44, 21-32.	0.2	3
43	Risankizumab. <i>Hospital Pharmacy</i> , 2019, , 001857871987387.	0.4	1
44	Risankizumab for the treatment of moderate to severe psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1-8.	1.4	8
45	Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal. <i>British Journal of Dermatology</i> , 2019, 180, 1348-1351.	1.4	9
46	Tildrakizumab: A Review of Phase II and III Clinical Trials. <i>Annals of Pharmacotherapy</i> , 2019, 53, 413-418.	0.9	18
47	Antibodies to watch in 2019. <i>MAbs</i> , 2019, 11, 219-238.	2.6	387
48	The ties that bind: skin, gut and spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2019, 31, 62-69.	2.0	36
49	Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks. <i>British Journal of Dermatology</i> , 2020, 182, 605-617.	1.4	103
50	Biologics for chronic inflammatory skin diseases: an update for the clinician. <i>Journal of Dermatological Treatment</i> , 2020, 31, 108-130.	1.1	17
51	Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 537-549.e10.	0.6	130
52	IM-UNITI at Three Years: Stellar Stelara® or Stardust? The Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1-3.	0.6	6
53	Biologic therapies targeting the interleukin (IL)-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 30-38.	1.3	36
54	Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 378-387.	2.3	13

#	ARTICLE	IF	CITATIONS
55	Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis. <i>Annals of Pharmacotherapy</i> , 2020, 54, 380-387.	0.9	11
56	Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses. <i>Dermatology and Therapy</i> , 2020, 10, 73-86.	1.4	38
57	Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis. <i>Clinical Pharmacokinetics</i> , 2020, 59, 575-589.	1.6	15
58	Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 435-442.	2.3	14
59	Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 39-46.	1.3	36
60	Japanese guidance for use of biologics for psoriasis (the 2019 version). <i>Journal of Dermatology</i> , 2020, 47, 201-222.	0.6	58
61	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <i>The Cochrane Library</i> , 2020, 1, CD011535.	1.5	86
62	Novedades terapéuticas en dermatología. <i>Piel</i> , 2020, 35, 4-9.	0.0	0
63	Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1151-1160.	1.3	59
64	Interleukin-17 cytokines: Effectors and targets in psoriasis—A breakthrough in understanding and treatment. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	54
65	Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	55
66	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 936-945.	0.6	71
67	Antibodies to watch in 2020. <i>MAbs</i> , 2020, 12, 1703531.	2.6	381
68	Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients. <i>Clinical Pharmacokinetics</i> , 2020, 59, 311-326.	1.6	20
69	Anti-interleukin-23 agents for the treatment of ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 399-406.	1.4	41
70	Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1252-1256.	1.1	4
71	New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?. <i>Current Opinion in Pharmacology</i> , 2020, 55, 141-150.	1.7	17
72	The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. <i>Frontiers in Immunology</i> , 2020, 11, 594735.	2.2	135

#	ARTICLE	IF	CITATIONS
73	Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 625-632.	0.6	5
74	The TNF/IL-23/IL-17 axis—Head-to-head trials comparing different biologics in psoriasis treatment. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12946.	1.3	58
75	Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 1344.	2.0	29
76	Update on risankizumab for the treatment of moderate to severe psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1245-1251.	1.4	5
77	Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis. <i>Dermatology</i> , 2021, 237, 158-165.	0.9	3
78	Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 881-890.	3.3	24
79	Skin manifestations in spondyloarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2097591.	1.2	15
80	Emerging role of anti-IL23 in the treatment of psoriasis: When humanized is very promising. <i>Dermatologic Therapy</i> , 2020, 33, e14504.	0.8	29
81	A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque Psoriasis treated with Biologics in a REAL world setting (PSO-BIO-REAL). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2566-2573.	1.3	19
82	Pathophysiology, Clinical Presentation, and Treatment of Psoriasis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1945.	3.8	953
83	Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: <i>post-hoc</i> analysis from the phase III, double-blind, placebo- and active-comparator-controlled VOYAGE 1/2 trials. <i>Journal of Dermatological Treatment</i> , 2022, 33, 535-541.	1.1	5
84	IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. <i>Clinical and Experimental Immunology</i> , 2020, 201, 121-134.	1.1	66
85	The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis?. <i>Current Opinion in Rheumatology</i> , 2020, 32, 349-356.	2.0	14
86	Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days. <i>Dermatologic Therapy</i> , 2020, 33, e13686.	0.8	9
87	Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. <i>Dermatologic Therapy</i> , 2020, 33, e13687.	0.8	45
88	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712.	0.5	609
89	Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review. <i>Dermatologic Therapy</i> , 2020, 33, e13800.	0.8	6
90	Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	5.7	68

#	ARTICLE	IF	CITATIONS
91	An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan. <i>Journal of Dermatological Treatment</i> , 2022, 33, 229-239.	1.1	4
92	Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 211-232.	1.3	12
93	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 431-447.	1.4	40
94	Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. <i>Journal of Dermatological Treatment</i> , 2022, 33, 204-218.	1.1	40
95	Interleukin 23 and autoimmune diseases: current and possible future therapies. <i>Inflammation Research</i> , 2020, 69, 463-480.	1.6	20
96	New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers. <i>Biochemical Pharmacology</i> , 2020, 175, 113928.	2.0	51
97	COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement. <i>Australasian Journal of Dermatology</i> , 2020, 61, 210-216.	0.4	43
98	Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1690.	1.8	117
99	Risankizumab: A Review in Moderate to Severe Plaque Psoriasis. <i>Drugs</i> , 2020, 80, 1235-1245.	4.9	21
100	A Nonsystematic Review on Risankizumab: a Novel Drug Recently Approved for Moderate to Severe Psoriasis. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1174-1180.	0.3	1
101	<sc>COVID</sc> -19 infection on <sc>IL</sc> -23 inhibition. <i>Dermatologic Therapy</i> , 2020, 33, e13893.	0.8	16
102	Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration. <i>International Journal of Dermatology</i> , 2020, 59, 1043-1056.	0.5	19
103	Efficacy and safety of guselkumab for the treatment of patients with moderate-to-severe plaque psoriasis: A metaanalysis of randomized clinical trials. <i>Tropical Journal of Pharmaceutical Research</i> , 2020, 19, 433-440.	0.2	0
104	Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry. <i>Journal of Dermatological Treatment</i> , 2020, 32, 1-9.	1.1	1
105	A drug safety evaluation of risankizumab for psoriasis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 395-402.	1.0	18
106	Reliability, validity, and the ability to detect change of the Psoriasis Symptom Scale (PSS) in patients with plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2020, 31, 460-469.	1.1	6
107	Safety concerns with current treatments for psoriasis in the elderly. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 523-531.	1.0	20
108	Successful use of guselkumab in the treatment of severe hidradenitis suppurativa. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 618-619.	0.6	21

#	ARTICLE	IF	CITATIONS
109	Therapies in Inflammatory Bowel Disease Patients with Extraintestinal Manifestations. <i>Digestion</i> , 2020, 101, 83-97.	1.2	19
110	The role of antibody delivery formation in cancer therapy. <i>Journal of Drug Targeting</i> , 2020, 28, 574-584.	2.1	5
111	Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1546-1555.e4.	0.3	40
112	Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. <i>Journal of Dermatological Treatment</i> , 2022, 33, 219-228.	1.1	17
113	Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 649.	2.0	120
114	Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis. <i>Viruses</i> , 2020, 12, 438.	1.5	4
115	Successful treatment of a refractory pyoderma gangrenosum with risankizumab. <i>International Wound Journal</i> , 2020, 17, 1086-1088.	1.3	17
116	Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltimMa1 and UltimMa2 studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2830-2838.	1.3	46
117	Challenges of COVID-19 pandemic for dermatology. <i>Dermatologic Therapy</i> , 2020, 33, e13430.	0.8	62
118	Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times. <i>Dermatology and Therapy</i> , 2020, 10, 339-349.	1.4	37
119	Head-to-head trials in inflammatory bowel disease: past, present and future. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 365-376.	8.2	37
120	Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis – efficacy findings up to week 12. <i>Journal of Dermatological Treatment</i> , 2022, 33, 54-61.	1.1	7
121	Guselkumab vs. secukinumab for the treatment of moderate-to-severe psoriasis: a critical appraisal. <i>British Journal of Dermatology</i> , 2021, 184, 259-260.	1.4	2
122	Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial*. <i>British Journal of Dermatology</i> , 2021, 184, 50-59.	1.4	119
123	Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta-analysis. <i>Dermatologic Therapy</i> , 2021, 34, e14487.	0.8	15
124	The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 676-690.	0.6	9
125	Interleukin 23 Inhibitors. , 2021, , 321-329.e2.		0
126	Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 130-138.	0.6	20

#	ARTICLE	IF	CITATIONS
127	Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINEâ€2 and â€3. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 450-457.	1.3	14
128	Complete skin clearance and beyond. British Journal of Dermatology, 2021, 184, 3-4.	1.4	3
129	Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience. Dermatologic Therapy, 2021, 34, e14584.	0.8	29
130	IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases. Clinical Reviews in Allergy and Immunology, 2021, 60, 31-45.	2.9	14
131	Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. American Journal of Clinical Dermatology, 2021, 22, 173-192.	3.3	79
132	Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis*. British Journal of Dermatology, 2021, 184, 1094-1105.	1.4	39
133	A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e169-e170.	1.3	31
134	Role of interleukin-23/interleukin-17 axis in T-cell-mediated actions in hypertension. Cardiovascular Research, 2021, 117, 1274-1283.	1.8	19
135	Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates. Journal of Clinical Pharmacology, 2021, 61, 307-318.	1.0	3
136	Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. Journal of Dermatological Treatment, 2021, 32, 302-309.	1.1	11
137	Advancements in Biologic Therapy for Psoriasis: the IL-23 Inhibitors. Current Dermatology Reports, 2021, 10, 6-15.	1.1	1
138	Wirksamkeit und Sicherheit von Biologika bei Psoriasis und Psoriasis-Arthritis und ihre Auswirkungen auf KomorbiditÄten: eine Literatur-Übersicht. Karger Kompass Dermatologie, 2021, 9, 2-8.	0.0	0
139	Psoriasis: Recent progress in molecular-targeted therapies. Journal of Dermatology, 2021, 48, 761-777.	0.6	39
140	Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 84-94.	0.5	5
141	The Importance of Cardiac Assessment in the Era of Biologic Therapies for Psoriasis. , 2021, , 419-430.		0
142	PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. Journal of Dermatological Treatment, 2022, 33, 1661-1669.	1.1	15
143	Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single-center real-life population. Journal of Dermatological Treatment, 2022, 33, 1638-1642.	1.1	18
144	Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies. Frontiers in Immunology, 2021, 12, 621956.	2.2	48

#	ARTICLE	IF	CITATIONS
145	Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values 1, 2, 3 or 5 derived from a statistical conversion method. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1161-1175.	1.3	13
146	What is new in dermatotherapy?. Indian Journal of Dermatology, Venereology and Leprology, 2021, 87, 135-143.	0.2	0
147	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 281-317.	1.3	84
148	Biologic Treatments of Psoriasis: An Update for the Clinician. Biologics: Targets and Therapy, 2021, Volume 15, 39-51.	3.0	40
149	Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Archives of Dermatological Research, 2022, 314, 619-623.	1.1	39
150	<sc>LncRNA UCA1</sc> negatively regulates <sc>NF-κB</sc> activity in psoriatic keratinocytes through the <sc>miR125a</sc> axis. Kaohsiung Journal of Medical Sciences, 2021, 37, 172-180.	0.8	12
151	Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet, The, 2021, 397, 754-766.	6.3	222
152	Cytokine fine tuning of enthesis tissue homeostasis as a pointer to spondyloarthritis pathogenesis with a focus on relevant TNF and IL-17 targeted therapies. Seminars in Immunopathology, 2021, 43, 193-206.	2.8	14
153	Speed of Psoriasis Treatment Response for Biologic Agents: A Review of Phase III Clinical Trials. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 99-105.	0.3	1
154	Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy, 2021, 11, 885-905.	1.4	40
156	Perspectives on the Genetic Associations of Ankylosing Spondylitis. Frontiers in Immunology, 2021, 12, 603726.	2.2	15
157	Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study. Lancet Rheumatology, The, 2021, 3, e204-e213.	2.2	15
158	Treatment of patients with atopic dermatitis with weekly dupilumab dosing: A single institutional retrospective medical record review and survey. Journal of the American Academy of Dermatology, 2022, 86, 1148-1149.	0.6	1
159	Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis. Journal of Dermatological Treatment, 2022, 33, 2094-2101.	1.1	5
160	TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors. International Journal of Dermatology, 2022, 61, 139-147.	0.5	23
161	Safety and Efficacy of Vaccines during COVID-19 Pandemic in Patients Treated with Biological Drugs in a Dermatological Setting. Healthcare (Switzerland), 2021, 9, 401.	1.0	8
162	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. The Cochrane Library, 2021, 2021, CD011535.	1.5	34
163	Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review. American Journal of Clinical Dermatology, 2021, 22, 425-442.	3.3	55

#	ARTICLE	IF	CITATIONS
164	Psoriasis. Lancet, The, 2021, 397, 1301-1315.	6.3	792
165	Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma. JAAD Case Reports, 2021, 11, 74-77.	0.4	17
166	Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World Journal of Gastroenterology, 2021, 27, 2312-2324.	1.4	13
167	Efficacy, safety, usability, and acceptability of risankizumab 150mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. Journal of Dermatological Treatment, 2022, 33, 2085-2093.	1.1	7
168	The road to personalised medicine in psoriatic arthritis. Expert Review of Clinical Immunology, 2021, 17, 799-802.	1.3	0
169	Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model. Dermatology and Therapy, 2021, 11, 1291-1304.	1.4	5
170	Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. International Journal of Molecular Sciences, 2021, 22, 4983.	1.8	40
171	Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis. Frontiers in Immunology, 2021, 12, 622770.	2.2	21
172	New possibilities of systemic therapy of plaque psoriasis with the IL23p19 inhibitor risankizumab. Meditsinskiy Sovet, 2021, , 40-50.	0.1	0
173	Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. Journal of Crohn's and Colitis, 2021, 15, 2001-2010.	0.6	27
174	Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic. Dermatology and Therapy, 2021, 11, 1345-1355.	1.4	29
175	Safety and Efficacy of Risankizumab and Infliximab in the Treatment of Plaque Psoriasis: Results From a Direct and Indirect Meta-Analysis. Cureus, 2021, 13, e15963.	0.2	1
176	New targets in inflammatory bowel disease therapy: 2021. Current Opinion in Gastroenterology, 2021, 37, 357-363.	1.0	31
177	Model-Based Meta-Analysis in Psoriasis: A Quantitative Comparison of Biologics and Small Targeted Molecules. Frontiers in Pharmacology, 2021, 12, 586827.	1.6	6
178	Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy of patients with moderate to severe plaque psoriasis: a phase 3 clinical trial. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1686-1691.	1.3	12
179	Saudi consensus statement on biologic treatment of chronic plaque psoriasis (2020). Journal of Dermatological Treatment, 2021, , 1-15.	1.1	1
180	Newer Therapies in Psoriasis. Medical Clinics of North America, 2021, 105, 627-641.	1.1	10
181	Direct comparison of risankizumab and fumaric acid esters in systemic therapy of patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. British Journal of Dermatology, 2022, 186, 30-39.	1.4	9

#	ARTICLE	IF	CITATIONS
182	Establishment of an Intradermal Ear Injection Model of IL-17A and IL-36 ^{Î³} as a Tool to Investigate the Psoriatic Cytokine Network. <i>Life</i> , 2021, 11, 846.	1.1	1
183	A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. <i>Frontiers in Medicine</i> , 2021, 8, 702776.	1.2	9
186	Dihydroartemisinin Alleviates Imiquimod-Induced Psoriasis-like Skin Lesion in Mice Involving Modulation of IL-23/Th17 Axis. <i>Frontiers in Pharmacology</i> , 2021, 12, 704481.	1.6	5
187	Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 572-581.	0.6	36
188	Tâ€œcell subsets in the skin and their role in inflammatory skin disorders. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 827-842.	2.7	27
189	Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy. <i>Global & Regional Health Technology Assessment</i> , 0, 8, 120-130.	0.2	1
190	Risankizumab in the treatment of erythrodermic form of psoriasis in patient with associated scleroderma. <i>Dermatologie Pro Praxi</i> , 2021, 15, 89-93.	0.1	0
191	Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2021, 11, 1965-1998.	1.4	14
192	Psoriasis and Atherosclerosisâ€™ Skin, Joints, and Cardiovascular Story of Two Plaques in Relation to the Treatment with Biologics. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10402.	1.8	8
193	Longâ€™term efficacy and safety of risankizumab for the treatment of moderateâ€™toâ€™severe plaque psoriasis: interim analysis of the LIMMitless openâ€™label extension trial beyond 3 years of followâ€™up. <i>British Journal of Dermatology</i> , 2021, 185, 1135-1145.	1.4	28
194	Bimekizumab versus Adalimumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 1149-1150.	13.9	3
195	Immunomodulatory Properties of Umbilical Cord Blood-Derived Small Extracellular Vesicles and Their Therapeutic Potential for Inflammatory Skin Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9797.	1.8	9
196	Psoriasis medications: The future. <i>Dermatological Reviews</i> , 2021, 2, 296-305.	0.3	1
197	New Frontiers in Psoriatic Disease Research,â€™Part II: Comorbidities and Targeted Therapies. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2328-2337.	0.3	21
198	Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial. <i>Dermatology and Therapy</i> , 2021, 11, 487-497.	1.4	3
199	Immune responses and therapeutic options in psoriasis. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 2709-2727.	2.4	25
200	Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. <i>Dermatology and Therapy</i> , 2021, 11, 385-400.	1.4	29
202	A Systematic Review With Network Meta-Analysis of the Available Biologic Therapies for Psoriatic Disease Domains. <i>Frontiers in Medicine</i> , 2020, 7, 618163.	1.2	14

#	ARTICLE	IF	CITATIONS
203	A non-clinical comparative study of IL-23 antibodies in psoriasis. <i>MABs</i> , 2021, 13, 1964420.	2.6	18
204	Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00605.	0.6	24
205	Comparison of Biologics and Oral Treatments for Plaque Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 258.	2.0	169
206	Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1631-1638.	1.1	12
207	A Brief History of Psoriasis Management in Canada. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 273-277.	0.6	1
208	Risk for Deep Fungal Infections During IL-17 and IL-23 Inhibitor Therapy for Psoriasis. , 2020, 106, 199-205.		10
209	IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2019, 57, 400-406.	0.2	12
210	<p></p>Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis</p></p>. <i>Journal of Inflammation Research</i> , 2020, Volume 13, 53-60.	1.6	16
211	Psoriasis and Treatment: Past, Present and Future Aspects. <i>Acta Dermato-Venereologica</i> , 2020, 100, 70-80.	0.6	77
212	Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis. <i>Minerva Medica</i> , 2020, 111, 254-265.	0.3	4
213	IL-12 regulates type 3 immunity through interfollicular keratinocytes in psoriasiform inflammation. <i>Science Immunology</i> , 2021, 6, eabg9012.	5.6	14
215	Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis*. <i>British Journal of Dermatology</i> , 2022, 186, 466-475.	1.4	41
216	Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study*. <i>British Journal of Dermatology</i> , 2022, 186, 652-663.	1.4	22
217	Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors. <i>Dermatology and Therapy</i> , 2021, 11, 2027-2042.	1.4	2
218	Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 1002-1014.	3.7	114
219	Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 561-567.	0.6	55
221	Scalp Psoriasis. , 2020, , 177-195.		1
222	Quoi de neuf en th�rapeutique dermatologique ?. <i>Annales De Dermatologie Et De Venereologie</i> , 2019, 146, 12S46-12S51.	0.5	0

#	ARTICLE	IF	CITATIONS
223	Risankizumab (Skyrizi). <i>Dermatologie Pro Praxi</i> , 2020, 14, 91-95.	0.1	0
224	Which PASI Outcome Is Most Relevant to the Patients in Real-World Care?. <i>Life</i> , 2021, 11, 1151.	1.1	6
225	Clinical Translation of Basic Science in Asthma. <i>New England Journal of Medicine</i> , 2021, 385, 1714-1717.	13.9	4
226	Biologics update: IL-23 inhibitors. <i>Dermatological Reviews</i> , 2021, 2, 276.	0.3	0
227	Risankizumab in Severe Asthma – A Phase 2a, Placebo-Controlled Trial. <i>New England Journal of Medicine</i> , 2021, 385, 1669-1679.	13.9	54
228	Personalised Medicine with IL-23 Blockers: Myth or Reality?. <i>Journal of Crohn's and Colitis</i> , 2022, 16, ii73-ii94.	0.6	10
229	Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 47-56.	0.4	12
230	The effectiveness and safety study of topical corticosteroids for psoriasis in adolescent and adult population treatment. <i>ZaporoÅ¼skij Medicinskij Å½urnal</i> , 2020, .	0.0	0
231	<i>Neue Arzneimittel 2019.</i> , 2020, , 43-150.		2
232	How current biologic therapies affect the risk of major adverse cardiovascular events in patients with plaque psoriasis? A systematic review and meta-analysis of randomized controlled trials. <i>Postepy Dermatologii i Alergologii</i> , 2020, 37, 986-994.	0.4	2
233	New drug: Risankizumab for psoriasis. <i>Australian Prescriber</i> , 2020, 43, 70-71.	0.5	1
234	Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis. <i>Frontiers in Pharmacology</i> , 2021, 12, 774808.	1.6	16
235	Risankizumab vs. fumaric acid esters: a direct comparison. <i>British Journal of Dermatology</i> , 2021, , .	1.4	0
236	Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. <i>Gastroenterology</i> , 2022, 162, 495-508.	0.6	60
237	Risankizumab. , 2021, , 235-241.		0
238	Current Developments in the Immunology of Psoriasis. <i>Yale Journal of Biology and Medicine</i> , 2020, 93, 97-110.	0.2	56
239	Innovations in Psoriasis Management: Based on Selected Presentations from the Symposium for Cosmetic Advances & Laser Education (SCALE) Virtual Congress-July 24 to 26, 2020. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2020, 13, S8-S23.	0.1	0
240	The Psoriasis Decision Tree. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2021, 14, 14-22.	0.1	0

#	ARTICLE	IF	CITATIONS
241	Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study. <i>JAAD International</i> , 2022, 6, 3-5.	1.1	2
242	Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPSAKE 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 351-358.	0.5	56
243	Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients. <i>Dermatology</i> , 2022, 238, 615-619.	0.9	26
244	Real world practice indirect comparison between guselkumab and risankizumab: Results from an <sc>Italian</sc> retrospective study. <i>Dermatologic Therapy</i> , 2022, 35, e15214.	0.8	35
245	The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12793.	1.8	50
246	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110579.	1.2	30
247	IL-23 blockers in dermatology. <i>Indian Journal of Drugs in Dermatology</i> , 2021, 7, 51.	0.0	0
248	Severe and resistant palmar psoriasis successfully treated with risankizumab. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, .	0.1	2
249	Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management. <i>Psoriasis: Targets and Therapy</i> , 2022, Volume 12, 1-14.	1.2	7
250	Anti-interleukin-23 directed therapy and the recurrence of severe allergic asthma. <i>Rheumatology</i> , 2022, , .	0.9	2
252	Role of Interleukin 36 in Generalised Pustular Psoriasis and Beyond. <i>Dermatology and Therapy</i> , 2022, 12, 315-328.	1.4	18
253	Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. <i>Dermatology and Therapy</i> , 2022, 12, 561-575.	1.4	7
254	No Evidence that Variations in Ambient Solar Ultraviolet Radiation and Psoriasis Severity are Associated. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 0, , 247553032210798.	0.3	1
255	Psoriasis ungueal. <i>Actas Dermo-sifiligráficas</i> , 2022, 113, 481-490.	0.2	14
256	What Can IBD Specialists Learn from IL-23 Trials in Dermatology?. <i>Journal of Crohn's and Colitis</i> , 2022, 16, ii20-ii29.	0.6	10
257	[Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy. <i>Actas Dermo-sifiligráficas</i> , 2022, 113, T261-T277.	0.2	4
258	Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. <i>Gastroenterology</i> , 2022, 162, 1650-1664.e8.	0.6	88
259	Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma. <i>Cancer Science</i> , 2022, 113, 1208-1219.	1.7	6

#	ARTICLE	IF	CITATIONS
260	Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 225-231.	0.5	73
262	Immunopathology and Immunotherapy of Inflammatory Skin Diseases. <i>Immune Network</i> , 2022, 22, e7.	1.6	13
264	Safety in numbers: risankizumab for moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2022, 186, 394-395.	1.4	0
265	Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 727-740.	1.4	9
266	Break on through: The role of innate immunity and barrier defence in atopic dermatitis and psoriasis. <i>Skin Health and Disease</i> , 2022, 2, .	0.7	6
267	Risankizumab shows high efficacy and maintenance in improvement of response until week 52. <i>Dermatologic Therapy</i> , 2022, 35, e15378.	0.8	20
268	Novel Therapeutic Target(s) for Psoriatic Disease. <i>Frontiers in Medicine</i> , 2022, 9, 712313.	1.2	9
269	Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, , .	1.9	0
270	Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis. <i>Advances in Therapy</i> , 2022, 39, 2256-2269.	1.3	10
271	Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a <i>post hoc</i> integrated analysis of patients with moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 855-865.	1.3	11
272	Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis. <i>Pharmaceutics</i> , 2022, 14, 654.	2.0	9
273	Immunobiologicals in dermatology. <i>Anais Brasileiros De Dermatologia</i> , 2022, , .	0.5	1
274	Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study. <i>Dermatologic Therapy</i> , 2022, 35, e15489.	0.8	13
275	Emerging Treatment Regimens in Psoriasis: Are There Advantages Over Current Biologic Therapies?. <i>EMJ Dermatology</i> , 0, , 106-121.	0.0	1
276	Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 167-184.	1.4	22
277	Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials. <i>Dermatology and Therapy</i> , 2022, 12, 407-418.	1.4	6
278	The Role of Helper T Cells in Psoriasis. <i>Frontiers in Immunology</i> , 2021, 12, 788940.	2.2	70
279	Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 105-107.	1.4	3

#	ARTICLE	IF	CITATIONS
280	[Translated article] Nail Psoriasis. Actas Dermo-sifiliográficas, 2022, 113, T481-T490.	0.2	4
281	Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study. Dermatologic Therapy, 2022, 35, e15524.	0.8	43
282	Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 941-953.	0.7	3
286	Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study. Dermatology and Therapy, 2022, 12, 1263-1270.	1.4	13
287	Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry. Rheumatology and Therapy, 2022, 9, 1031-1047.	1.1	9
288	Is risankizumab as needed administration a good option for patients with plaque psoriasis?. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	3
289	Crohn's Disease of the Elderly. Gastroenterology Clinics of North America, 2022, 51, 425-440.	1.0	5
290	Annoying Psoriasis and Atopic Dermatitis: A Narrative Review. International Journal of Molecular Sciences, 2022, 23, 4898.	1.8	16
291	Emerging therapies for ulcerative colitis. Expert Review of Clinical Immunology, 2022, 18, 513-524.	1.3	13
292	Skin Inflammation Modulation via TNF- α , IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis. International Journal of Molecular Sciences, 2022, 23, 5198.	1.8	4
293	Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center. Biomedicines, 2022, 10, 1058.	1.4	4
294	Interleukin-23 Inhibitors. Turkderm, 0, , 61-66.	0.0	0
295	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. The Cochrane Library, 2022, 2022, .	1.5	25
296	Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet, The, 2022, 399, 2015-2030.	6.3	126
297	Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors " brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry. Journal of Dermatological Treatment, 2022, 33, 2827-2837.	1.1	11
298	Choice of therapy for psoriasis: inhibition of IL-23 p19 " data from clinical studies and real practice. Medical Alphabet, 2022, , 71-74.	0.0	0
299	Keratinocytes in Skin Disorders: The Importance of Keratinocytes as a Barrier. , 0, , .		0
300	Endothelial Dysfunction in Psoriasis: An Updated Review. Frontiers in Medicine, 0, 9, .	1.2	12

#	ARTICLE	IF	CITATIONS
301	Risankizumab shows faster response in bio naïve than in bioexperienced psoriatic patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	11
302	Treating psoriasis in the elderly: biologics and small molecules. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1503-1520.	1.4	30
303	The seroconversion rate of QuantiFERON-TB gold in-tube test in psoriatic patients receiving anti-interleukin-23 monoclonal antibodies. <i>Dermatologica Sinica</i> , 2022, 40, 94.	0.2	3
304	The Role of Interleukin-23 Inhibition in the Treatment of Psoriatic Arthritis. , 2022, 1, 18.		0
305	Integrating new and emerging therapies into inflammatory bowel disease clinical practice. <i>Current Opinion in Gastroenterology</i> , 2022, 38, 328-336.	1.0	3
306	Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics. <i>Italian Journal of Dermatology and Venereology</i> , 2023, 157, .	0.1	1
307	Switching from <scp>IL23</scp> inhibitors to <scp>IL17</scp> inhibitors: A safe and effective practice?. <i>Dermatologic Therapy</i> , 2022, 35, .	0.8	6
308	Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. <i>Journal of Dermatological Treatment</i> , 0, , 1-9.	1.1	1
309	Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). <i>British Journal of Dermatology</i> , 2022, 187, 866-877.	1.4	17
310	Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 1777-1792.	1.4	22
311	The Value of Indirect Comparisons of Systemic Biologics for Psoriasis: Interpretation of Efficacy Findings. <i>Dermatology and Therapy</i> , 2022, 12, 1711-1727.	1.4	2
312	Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1. <i>Rheumatology</i> , 2023, 62, 629-637.	0.9	4
313	Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached?. <i>European Journal of Pharmacology</i> , 2022, 929, 175147.	1.7	8
314	The impact of the first COVID-19 wave on office-based dermatological care in Germany: a focus on diagnosis, therapy and prescription of biologics. <i>European Journal of Dermatology</i> , 2022, 32, 195-206.	0.3	1
315	Spondyloarthritis in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets. <i>Drugs</i> , 2022, 82, 1151-1163.	4.9	2
316	Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review. <i>Journal of Dermatological Treatment</i> , 2022, 33, 3086-3097.	1.1	9
317	Comparison of the Inflammatory Circuits in Psoriasis Vulgaris, Non-Pustular Palmoplantar Psoriasis, and Palmoplantar Pustular Psoriasis. <i>Journal of Investigative Dermatology</i> , 2023, 143, 87-97.e14.	0.3	7
318	Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation. <i>Dermatology and Therapy</i> , 2022, 12, 2063-2075.	1.4	2

#	ARTICLE	IF	CITATIONS
319	Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review. <i>Dermatology and Therapy</i> , 2022, 12, 2201-2216.	1.4	6
320	Distinct spatial and temporal roles for Th1, Th2, and Th17 cells in asthma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	18
321	A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment. <i>Journal of Immunology Research</i> , 2022, 2022, 1-11.	0.9	4
322	Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial. <i>Rheumatology and Therapy</i> , 2022, 9, 1361-1375.	1.1	8
323	Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 0, Volume 15, 1649-1658.	0.8	47
324	Towards Personalized Medicine in Psoriasis: Current Progress. <i>Psoriasis: Targets and Therapy</i> , 0, Volume 12, 231-250.	1.2	14
325	Biologics: how far can they go in Crohn's disease?. <i>Gastroenterology Report</i> , 2022, 10, .	0.6	9
326	Cytokine Modulators in Plaque Psoriasis—A Review of Current and Prospective Biologic Therapeutic Approaches. <i>JAAD International</i> , 2022, 9, 82-91.	1.1	2
327	The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. <i>Musculoskeletal Care</i> , 2022, 20, .	0.6	13
328	Looking beyond the Skin: Pathophysiology of Cardiovascular Comorbidity in Psoriasis and the Protective Role of Biologics. <i>Pharmaceuticals</i> , 2022, 15, 1101.	1.7	6
329	Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab. <i>Vestnik Dermatologii i Venerologii</i> , 2022, 98, 23-30.	0.2	0
330	Biological treatment for erythrodermic psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1531-1543.	1.4	4
331	Risk of Candida Infection and Serious Infections in Patients with Moderate-to-Severe Psoriasis Receiving Biologics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-11.	0.8	5
332	Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
333	Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study. <i>Dermatology and Therapy</i> , 2022, 12, 2309-2324.	1.4	22
334	Landscape of new drugs and targets in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2022, 10, 1129-1166.	1.6	10
335	Resident Memory T Cells in Psoriasis: Key to a Cure?. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2022, 7, 157-159.	0.3	2
336	Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA). <i>Scientific Reports</i> , 2022, 12, .	1.6	11

#	ARTICLE	IF	CITATIONS
337	Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. <i>Journal of Dermatological Treatment</i> , 2023, 34, .	1.1	8
338	Pathogenesis, multi-omics research, and clinical treatment of psoriasis. <i>Journal of Autoimmunity</i> , 2022, 133, 102916.	3.0	21
339	Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPSAKE 2 study. <i>Rheumatology</i> , 2023, 62, 2122-2129.	0.9	8
340	Anti-IL 23 biologics for the treatment of plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1489-1502.	1.4	7
341	Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPSAKE 1 study. <i>Rheumatology</i> , 2023, 62, 2113-2121.	0.9	7
342	Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study. <i>F1000Research</i> , 0, 11, 1178.	0.8	1
343	Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis. <i>Current Opinion in Pharmacology</i> , 2022, 67, 102292.	1.7	4
344	Discover the Potential: Exploring New Frontiers of IL-23 Inhibitors. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 12-19.	3.0	0
345	IL-23 Inhibition as a Key Component in Psoriasis Treatment is Here to Stay. <i>EMJ Dermatology</i> , 0, , 2-11.	0.0	0
346	IL-23 Inhibition as a Key Component in Psoriasis Treatment is Here to Stay. <i>EMJ Dermatology</i> , 0, , 2-11.	0.0	0
347	IL-23 Inhibition in Psoriasis: A Novel Approach to Convenient, Consistent Clearance. <i>EMJ Dermatology</i> , 0, , 2-11.	0.0	0
348	Is Complete Skin Clearance in Psoriasis the Answer?. <i>EMJ Dermatology</i> , 0, , 53-61.	0.0	0
349	IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability. <i>EMJ Dermatology</i> , 0, , 112-123.	0.0	0
350	Translating Knowledge of IL-23 Targeting into New Solutions for Psoriasis Treatment. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 16-22.	3.0	0
351	IL-23 Inhibition: From Pathophysiological Jungle to Clinical Clearance. <i>EMJ Dermatology</i> , 0, , 2-7.	0.0	0
352	2022 Taiwanese Dermatological Association (TDA), Taiwanese Association for Psoriasis and Skin Immunology (TAPSI), and Taiwan Society of cardiology (TSOC) joint consensus recommendations for the management of psoriatic disease with attention to cardiovascular comorbidities. <i>Journal of the Formosan Medical Association</i> . 2023. 122. 442-457.	0.8	4
353	Letter to the Editor: Does Ambient Ultraviolet Radiation Affect Psoriasis Severity. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 0, , 247553032211312.	0.3	0
354	Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study. <i>F1000Research</i> , 0, 11, 1178.	0.8	1

#	ARTICLE	IF	CITATIONS
355	Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines. <i>Life</i> , 2022, 12, 1883.	1.1	5
356	Pathways to Silencing Psoriasis: Remission or Cure?. <i>EMJ Dermatology</i> , 0, , 2-8.	0.0	0
358	Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness. <i>Life</i> , 2022, 12, 2050.	1.1	8
359	Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A <scp>GETAID</scp> multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 426-434.	1.9	10
360	Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data. <i>Immunologic Research</i> , 0, , .	1.3	2
361	Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?. <i>Current Rheumatology Reports</i> , 2023, 25, 56-67.	2.1	3
362	TH17 cell heterogeneity and its role in tissue inflammation. <i>Nature Immunology</i> , 2023, 24, 19-29.	7.0	38
363	Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. <i>BioDrugs</i> , 2023, 37, 35-55.	2.2	21
364	English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). <i>Journal of Dermatology</i> , 2023, 50, .	0.6	12
365	Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 0, Volume 16, 221-229.	0.8	2
366	Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn's Disease: Patient Selection and Reported Outcomes. <i>Drug Design, Development and Therapy</i> , 0, Volume 17, 273-282.	2.0	0
367	Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 43-58.	1.0	35
368	Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma. <i>Melanoma Research</i> , 2023, 33, 152-154.	0.6	4
369	Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: A systematic review and aggregate data meta-analysis of randomized controlled trials. <i>International Journal of Rheumatic Diseases</i> , 2023, 26, 625-637.	0.9	4
370	Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS). <i>British Journal of Dermatology</i> , 2023, 188, 793-794.	1.4	8
371	Risankizumab Therapy for Moderate-to-Severe Psoriasis: A Multi-Center, Long-Term, Real-Life Study from Poland. <i>Journal of Clinical Medicine</i> , 2023, 12, 1675.	1.0	5
372	Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 0, Volume 16, 529-536.	0.8	7
373	Efficacy and Safety of Therapeutic Proteins. , 2023, , 275-296.		0

#	ARTICLE	IF	CITATIONS
374	Approved Protein Therapeutics and Their Biochemical Targets. , 2023, , 199-232.		0
375	Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial. <i>Dermatology and Therapy</i> , 2023, 13, 1099-1111.	1.4	16
376	Living with Psoriasis Vulgaris and Multi-Treatment Failure: A Patient and Dermatologist Perspective. <i>Dermatology and Therapy</i> , 2023, 13, 857-866.	1.4	1
377	Identification of novel immune subtypes and potential hub genes of patients with psoriasis. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	0
378	A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries. <i>British Journal of Dermatology</i> , 2024, 190, 315-339.	1.4	1
379	Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2023, 34, .	1.1	0
380	IL-17 and -23 Inhibitors for the Treatment of Psoriasis. <i>European Medical Journal Allergy & Immunology</i> , 0, , .	0.0	1
381	Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab. <i>ImmunoHorizons</i> , 2023, 7, 273-285.	0.8	0
404	Versatile roles of innate lymphoid cells at the mucosal barrier: from homeostasis to pathological inflammation. <i>Experimental and Molecular Medicine</i> , 2023, 55, 1845-1857.	3.2	2
420	Signaling pathways and targeted therapies for psoriasis. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	6
427	Drug survival of guselkumab and risankizumab seems superior to other biologics. , 0, , .		0
428	Risk of Cutaneous T-Cell Lymphoma with Psoriasis Biologic Therapies. <i>Dermatology and Therapy</i> , 0, , .	1.4	0
451	Biologics: Beyond the Basics. , 0, , .		0